VOR
Wall Street just moved the goalposts
HC Wainwright gave Vor Biopharma a more upbeat tune-up, lifting its Q1 2026 EPS estimate to ($0.88) from ($1.65) and trimming its FY2026 loss forecast to ($3.93). It also kept the stock at Buy with a $31 target.
The part investors actually care about
This isn’t a product launch or a lab breakthrough — it’s the financial version of saying, “okay, maybe the treadmill isn’t quite as brutal as we thought.” For a biotech name like Vor, every little improvement in the projected loss path matters because cash burn is the thing everyone’s side-eyeing.
The longer runway story
HC Wainwright also laid out estimates for the rest of the year and beyond, including:
- Q2 2026 EPS: ($0.94)
- Q3 2026 EPS: ($1.02)
- Q4 2026 EPS: ($1.10)
- FY2027 EPS: ($3.87)
- FY2028 EPS: ($2.08)
- FY2029 EPS: $4.16
That last number is the real eyebrow-raiser. It implies the model sees Vor eventually flipping from “scientifically promising, financially moody” to profitable sometime down the road.
Big picture
Analyst estimate changes don’t always move a stock on their own, but they can matter a lot for pre-revenue biotech, where valuation is basically a tug-of-war between hope and burn rate. If you own Vor, this is a mild vote of confidence — not a victory lap.